Keane's Corner VL

Perspectives - Releasing the Brakes on Cancer Immunotherapy

Details
Perspectives - Releasing the Brakes on Cancer Immunotherapy commentary from a NEJM Perspectives Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestiga...

The Dose-Dependent Effect Of ADT For Localized Prostate Cancer On Adverse Cardiac Events

Details
The Dose-Dependent Effect Of Androgen Deprivation Therapy For Localized Prostate Cancer On Adverse Cardiac Events - Highlights of a recent publication Article Title: THE DOSE-DEPENDENT EFFECT OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER ON ADVERSE CARDIAC EVENTS ABSTRACT Objectives: To investigate the dose-dependent effect of androgen deprivation therapy (ADT) on adverse cardiac e...

ASCO 2015 - Docetaxel and/or Zoledronic Acid for Hormone-naïve Prostate Cancer

Details
ASCO 2015 - Docetaxel and/or Zoledronic Acid for Hormone-naïve Prostate Cancer: First Overall Survival Results from STAMPEDE Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT Click HERE to read the session highlights from ASCO 2015 BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS special...

ASCO 2015 - Prostate & Bladder Cancers

Details
ASCO 2015 - Prostate & Bladder Cancers Tom Keane, MBBCh, FRCSI, FACS discusses the following abstracts from ASCO 2015: Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients with metastatic castration-resistant prostate cancer and poor prognosis First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cance...

ASCO 2015 - Optimal Timing of Docetaxel for Metastatic Prostate Cancer

Details
ASCO 2015 - Optimal Timing of Docetaxel for Metastatic Prostate Cancer Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinve...

GU Cancers Symposium 2015 - Prostate Cancer

Details
GU Cancers Symposium 2015 - Prostate Cancer Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session highlights from GU Cancers Symposium 2015 ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiati...

Biopsy and Re-biopsy of the Prostate: Interview with E. David Crawford, MD

Details
Best Decision Markers for Biopsy and Re-biopsy of the Prostate: Interview with E. David Crawford, MD Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT Video Lecture by E. David Crawford, MD: What are Currently the Best Decision Markers for Biopsy and Re-biopsy of the Prostate? BIOGRAPHY Thomas E. Kea...

GU Cancers Symposium 2015 - Renal & Prostate Cancers

Details
GU Cancers Symposium 2015 - Renal & Prostate Cancers Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : Insights into E3805: The CHAARTED trial - Abstract BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has ser...

GU Cancers Symposium 2015 - Prostate Cancer

Details
GU Cancers Symposium 2015 - Prostate Cancer Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : Insights into E3805: The CHAARTED trial - Abstract GU Cancers Symposium 2015 - AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC GU Cancers Symposium 2015 - Bench to bedside: Androgen r...

Comparison of MR/Ultrasound Fusion-guided Biopsy with Ultrasound-guided Biopsy for PCa

Details
Comparison of MR/Ultrasound Fusion-Guided Biopsy with Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer - Abstract BIOGRA...